Drug Search Results
More Filters [+]

CDX-1307

Alternative Names: cdx-1307, cdx1307, cdx 1307
Latest Update: 2020-02-13
Latest Update Note: Clinical Trial Update

Product Description

CDX-1307 is an experimental vaccine that is designed to generate an immune response against a protein called human chorionic gonadotropin-beta (hCG-_). hCG-_ is made by several types of cancers, including bladder cancer, and has been shown to be associated with shorter times to development of metastases and reduced survival in bladder cancer. In this study, it is hoped that administering the CDX-1307 vaccine will cause the body's immune system to attack bladder cancer cells in order to kill them or otherwise keep them from spreading or coming back. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01094496)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Celldex
Company Location: HAMPTON NJ 08827
Company CEO: Anthony S. Marucci
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CDX-1307

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Bladder Cancer

Phase 1: Breast Cancer|Pancreatic Cancer|Ovarian Cancer|Colorectal Cancer|Bladder Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

The "N-ABLE" Study

P2

Terminated

Bladder Cancer

2011-07-01

CDX-1307-01

P1

Completed

Pancreatic Cancer|Breast Cancer|Colorectal Cancer|Ovarian Cancer|Bladder Cancer

2010-05-01

CDX1307-02

P1

Completed

Pancreatic Cancer|Breast Cancer|Colorectal Cancer|Bladder Cancer|Ovarian Cancer

2009-05-01

Recent News Events

Date

Type

Title